No Data
Frontage (01521) granted 33.15 million share options.
Frontage (01521) announced in a statement that on October 30, 2024 (after the trading session), according to the public...
Trending Industry Today: TIGERMED Leads Losses In CRO Stocks
Frontage Records Lower Net Profit for Nine Months to September
frontage Holdings (01521.HK) The earnings for the first three quarters are approximately 0.191 billion US dollars, a decrease of 3.6% year-on-year.
Frontage Holdings (01521.HK) announced on October 29th that its controlling shareholder, Hangzhou Tigermed Technology Co., Ltd. (a listed company on the main board of the Hong Kong Stock Exchange (stock code: 3347) and a listed company on the gem board of the Shenzhen Stock Exchange (stock code: 300347)), has published its unaudited third-quarter financial performance for the nine months ended September 30, 2024 on the Hong Kong Stock Exchange. In order to ensure that all shareholders can fairly and promptly access the company's information, the company hereby discloses the following unaudited comprehensive financial information of the group.
Hong Kong stocks abnormal | The concept of CRO rose sharply in early trading, with intensive support policies for innovative drugs coming out, and the Fed may cut interest rates again in November.
Early concept of CRO rose in the morning session, as of the deadline, Frontage (01521) rose 8.45%, closing at 0.77 Hong Kong dollars; Tigermed (03347) rose 5.28%, closing at 38.85 Hong Kong dollars; Asymchem Laboratories (06821) rose 5.16%, closing at 57.1 Hong Kong dollars; Pharmaron (03759) rose 4.56%, closing at 15.6 Hong Kong dollars; Wuxi Bio (02269) rose 3.77%, closing at 17.08 Hong Kong dollars.
Is It Time To Consider Buying Frontage Holdings Corporation (HKG:1521)?
Despite Hitting HK$1.67, Frontage Holdings Insiders Still Sold Too SoonNo Data
No Data
